Literature DB >> 8599396

Clinical and neuropsychological comparison of psychotic depression with nonpsychotic depression and schizophrenia.

D V Jeste1, S C Heaton, J S Paulsen, L Ercoli, J Harris, R K Heaton.   

Abstract

OBJECTIVE: This study compared the clinical and neuropsychological characteristics of patients with psychotic depression to those of patients with nonpsychotic depression and patients with schizophrenia.
METHOD: Two hundred eighteen patients over the age of 45, including 30 who met the DSM-III-R criteria for unipolar major depression with psychotic features, 28 with nonpsychotic unipolar major depression, and 160 with schizophrenia, were examined. Subjects were evaluated on several clinical measures as well as on neuropsychological tests of attention, learning, memory (retention), psychomotor speed, and motor skills.
RESULTS: The three groups were comparable in age and education. The severity of depressive symptoms in the depressed patients with and without psychosis was similar. The patients with psychotic depression were comparable to those with schizophrenia on the neuropsychological measures; they were more impaired than the patients with nonpsychotic depression on the measures of psychomotor speed, motor skills, attention, and learning. The cognitive deficits seemed to be trait-related.
CONCLUSIONS: The findings provide additional support for the validity of psychotic depression as a diagnostic category distinct from nonpsychotic depression.

Entities:  

Mesh:

Year:  1996        PMID: 8599396     DOI: 10.1176/ajp.153.4.490

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  19 in total

1.  Stress-level cortisol treatment impairs inhibitory control of behavior in monkeys.

Authors:  D M Lyons; J M Lopez; C Yang; A F Schatzberg
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Perceptions of problems and needs for service among middle-aged and elderly outpatients with schizophrenia and related psychotic disorders.

Authors:  Lisa A Auslander; Dilip V Jeste
Journal:  Community Ment Health J       Date:  2002-10

Review 3.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Bupropion normalizes cognitive performance in patients with depression.

Authors:  C Thomas Gualtieri; Lynda G Johnson
Journal:  MedGenMed       Date:  2007-01-31

5.  Neuropsychological profile in early-onset schizophrenia-spectrum disorders: measured with the MATRICS battery.

Authors:  Aina Holmén; Monica Juuhl-Langseth; Rune Thormodsen; Ingrid Melle; Bjørn Rishovd Rund
Journal:  Schizophr Bull       Date:  2009-02-17       Impact factor: 9.306

6.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

Review 7.  Co-occurring depressive symptoms in the older patient with schizophrenia.

Authors:  John W Kasckow; Sidney Zisook
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  Insular cortex abnormalities in psychotic major depression: relationship to gender and psychotic symptoms.

Authors:  Jeremy D Cohen; Taylor Nichols; Jennifer Keller; Rowena G Gomez; Alan F Schatzberg; Allan L Reiss
Journal:  Neurosci Res       Date:  2013-03-05       Impact factor: 3.304

Review 9.  Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms.

Authors:  Michael A Cirillo; Larry J Seidman
Journal:  Neuropsychol Rev       Date:  2003-06       Impact factor: 7.444

10.  A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia.

Authors:  S Kristian Hill; James L Reilly; Margret S H Harris; Cherise Rosen; Robert W Marvin; Ovidio Deleon; John A Sweeney
Journal:  Schizophr Res       Date:  2009-05-17       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.